Affiliation:
1. Endocrinology and Medical Sexology (ENDOSEX) Department of Systems Medicine University of Rome Tor Vergata Rome Italy
2. Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
3. Department of Andrology Xi'an Daxing Hospital Xi'an China
4. Peking University 3rd Hospital Beijing China
5. Peking University 1st Hospital Beijing China
6. Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing China
7. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin China
8. National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin China
9. Department of Urology First Affiliated Hospital of Anhui Medical University Hefei Anhui China
10. Department of Infertility and Sexual Medicine 3rd Affiliated Hospital, Sun Yat‐sen University Guangzhou China
11. Shenzhen Key Laboratory of Fertility Regulation Center of Assisted Reproduction and Embryology The University of Hong Kong‐Shenzhen Hospital Shenzhen China
12. A. Menarini Asia‐Pacific Medical Affairs Singapore Singapore
13. A. Menarini China Medical Affairs Shanghai China
Abstract
Premature ejaculation (PE), despite its wide prevalence, is largely underdiagnosed and undertreated. Being a multifactorial dysfunction with strong cultural characteristics, PE requires skillful attitudes in the psychosexological support, necessary to manage the patient's and the couple's expectations, as well as in the medical treatment. Dapoxetine is a short‐acting selective serotonin reuptake inhibitor approved for use in lifelong and acquired PE in a number of countries. Opinions, not always generated by the evidence‐based medicine, impacted the attitudes of Western andrologists, as a nocebo effect which produced a drug's Waterloo, characterized by low prescription rates much more built on the patients’ and doctors’ expectations than on costs, side effects, and efficacy.In the present study, we retrospectively reviewed real‐life data from eight Andrology and Sexual Medicine Public Centers in China to assess the prevalence of PE among attending patients, its association with erectile dysfunction, its subtype, and the proposed treatments. In 2019, among 156,486 patients coming to the centers, 32,667 visits having PE as the chief complaint were performed (20.9%). Almost all patients received treatment prescriptions (32,641 patients, 99.92%); 23,273 patients came back for a follow‐up visit in the subsequent 12 months (71.2% of those who initially received treatment). Dapoxetine, either alone or in combination with another therapy, was the most prevalent treatment, prescribed to 22,767 patients (69.7% of treated patients), followed by traditional Chinese medicine (TCM) (39.4%). At follow‐up, 8174 patients were unsatisfied with treatment, and a new treatment was proposed (35.12%). Dapoxetine was the best treatment, with an overall 27.1% switching rate when used either alone or in combination: Although the switching rate for Dapoxetine alone was 44.2%, the association of the same drug with psychotherapy resulted in much lower rates (19.5%) and reached a minimum of 12% when also combined with TCM demonstrating how cultural aspects and medical attitudes may dramatically impact on the therapy of a multifaceted, complex, and culture‐grounded sexual symptom such as PE.In conclusion, taking switching rates as surrogate markers of treatment failure, this real‐life study—the largest in the field—shows that in a more patient‐oriented (as in Chinese medical culture), and less symptom‐oriented (as in Western medical attitudes), Dapoxetine is a successful treatment for PE patients, with higher reliability when used alone or as part of combined and integrated therapies.
Funder
National Natural Science Foundation of China
Subject
Urology,Endocrinology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism